Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
its CEO, Maria Maccecchini, Ph.D., presented her paper, “Targeting
Increased Levels of Neurotoxic Proteins in Down Syndrome,
Alzheimer’s and Parkinson’s Animals Normalized Axonal Transport,
Cognition and Function,” at the
New York Academy of Sciences’ Alzheimer's
Disease Therapeutics: Alternatives to Amyloid 2020 Virtual
Conference on Friday, December 4, 2020.
Dr. Maccecchini’s presentation highlighted the
Company’s data that demonstrates by lowering amyloid, tau, and
alpha-synuclein, the Company’s lead candidate, ANVS401, restores
axonal transport and nerve cell health.
Hundreds of recent clinical trials individually
targeting amyloid, tau, or alpha-synuclein in AD, PD or Down
syndrome (DS) have failed. While these proteins at elevated levels
turn toxic, just targeting one is not enough to protect the brain
from neurodegeneration. Overexpression of neurotoxic proteins
drives downstream events that dysregulate axonal transport, lead to
inflammation, nerve cell death, and loss of function.
To test this hypothesis, trisomic DS mice were
treated with ANVS401, an orally available small molecule shown to
reduce amyloid precursor protein (APP), tau, and alpha-synuclein.
ANVS401 lowered APP and phospho-tau, reversed Rab5 hyperactivation
and restored retrograde transport. In transgenic APP-AD mice,
ANVS401 lowered APP and its fragments in the brain and fully
restored long-term potentiation, memory, and learning. In
transgenic alpha-synuclein PD mice, it lowered alpha-synuclein in
the gut and in the brain and fully restored affected functions.
“Let me explain the science of axonal transport
for non-scientists: If we think about it, it is obvious that the
brain is our information processing, storage and distribution
center. In order for us to function, our brain needs to direct
everything we do, say, feel and think. To do so, the bodies of the
nerve cells are located in the brain, they have long arms called
axons that crisscross the body and at the end of the arms there are
fingers, called synapses, that touch everything. The fingers need
to communicate with the body and the body needs to communicate with
the fingers, in order for the nerve cells, the brain and for us to
function. That communication is done by sending packages of
information up and down the arm. If that communication does not
work, the information flow is blocked, the nerve cells get sick and
the function associated with the sick nerve cells is lost. That is
why in neurodegenerative diseases functions are lost. These
functions can be in the brain: memory, learning, executive
function; or in the body: speech, shaking, gate; or in the eye:
sight,” stated Dr. Maccecchini. “Our approach to neurodegeneration
is unique when compared to the long list of failed trials
exclusively targeting amyloid. The NYAS conference, the first major
event of its type dedicated to non-amyloid approaches to AD,
provided a great opportunity to share our unique approach with the
scientific community.”
ANVS401 inhibits more than one neurotoxic
protein and, thereby, improves axonal transport and reverses the
toxic cascade leading to nerve cell death. The Company is presently
in two ongoing double-blind, placebo-controlled Phase 2a studies
that were designed to measure the toxic cascade that leads to nerve
cell death and expects preliminary data in both AD and PD patients
in the first quarter of 2021.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2024 to May 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From May 2023 to May 2024